Publications (41) MARÍA JOSÉ SERRANO FERNÁNDEZ publications

filter_list Internal Medicine

2025

  1. Evaluating MicroRNAs as diagnostic tools for lymph node metastasis in breast cancer: Findings from a systematic review and meta-analysis

    Critical Reviews in Oncology/Hematology, Vol. 207

  2. Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization

    Archivos de Bronconeumologia, Vol. 61, Núm. 3, pp. 156-165

2023

  1. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer

    Cancer, Vol. 129, Núm. 4, pp. 521-530

  2. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer

    Biomarker Research

  3. Circulating tumor cells in cancer-risk populations as a cancer interception tool

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 113-129

  4. microRNAs signature in relapse metastasis and de novo metastasis of breast cancer. A systematic review

    Critical Reviews in Oncology/Hematology, Vol. 188

2022

  1. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

    Theranostics, Vol. 12, Núm. 5, pp. 2150-2161

  2. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective

    Molecular Genetics and Genomics, Vol. 297, Núm. 3, pp. 859-871

2021

  1. Circulating tumor cells enumeration from the portal vein for risk stratification in early pancreatic cancer patients

    Cancers, Vol. 13, Núm. 24

  2. Cross‐resistance to abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by ar transcriptional reactivation

    Cancers, Vol. 13, Núm. 6, pp. 1-21

  3. Deep phenotypic characterisation of CTCs by combination of microfluidic isolation (Isoflux) and imaging flow cytometry (imagestream)

    Cancers, Vol. 13, Núm. 24

  4. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective

    Journal of Molecular Pathology, Vol. 2, Núm. 3, pp. 255-273

  5. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 11, pp. 1165-1178

  6. Sandwich-Type Electrochemical Paper-Based Immunosensor for Claudin 7 and CD81 Dual Determination on Extracellular Vesicles from Breast Cancer Patients

    Analytical Chemistry, Vol. 93, Núm. 2, pp. 1143-1153

2020

  1. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

    Critical Reviews in Oncology/Hematology

  2. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients

    Scientific Reports, Vol. 10, Núm. 1

  3. The polemic diagnostic role of TP53 mutations in liquid biopsies from breast, colon and lung cancers

    Cancers, Vol. 12, Núm. 11, pp. 1-17

2019

  1. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents

    Cells, Vol. 8, Núm. 11

  2. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

    Breast Cancer Research, Vol. 21, Núm. 1